2023 Fiscal Year Final Research Report
Qualitative study of neutralizing antibodies to clinical isolates of RSV over time to overcome RSV infection.
Project/Area Number |
21K07868
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
Research Institution | Fukushima Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
細矢 光亮 福島県立医科大学, 医学部, 教授 (80192318)
郷 勇人 福島県立医科大学, 医学部, 講師 (30443857)
佐藤 晶論 福島県立医科大学, 医学部, 准教授 (60423795)
|
Project Period (FY) |
2021-04-01 – 2024-03-31
|
Keywords | RSV / F蛋白 / 中和エピトープ / 中和抗体 / 塩基配列 / アミノ酸配列 |
Outline of Final Research Achievements |
Respiratory Syncytial Virus (RSV) infections do not have useful prophylactics such as vaccines or antibodies available to most people. In recent years, advances in science have led to a better understanding of the structure of RSV, which has led to the development of new prophylactic drugs and their use worldwide. In this study, viruses from children with RSV infection and sera from healthy adults were examined for viral mutations that make prophylactics ineffective. The results showed that viral mutations that make certain antibodies less effective are widespread in Japan. We also found that some factors are particularly important among the antibodies involved in the prevention of the onset and severity of RSV infection.
|
Free Research Field |
小児科学
|
Academic Significance and Societal Importance of the Research Achievements |
ウイルス含む微生物に対して有効な薬剤が開発されると、薬剤が効かない微生物が新たに現れたり、広くまん延することがあります。RSVも同様です。今回の結果が、すぐに現在利用可能なRSVへの予防薬には当てはまりませんが、RSVウイルスの継続的なモニタリングが重要であることを示しています。継続的なモニタリングにより、RSVへの予防薬を有効に用いることが出来ます。
|